AI Article Synopsis
- Pleomorphic adenoma is the most common type of salivary gland tumor, affecting 2-3.5 per 100,000 people annually, but its development process is still not fully understood.
- Researchers investigated the roles of growth differentiation factor 5 (GDF5) and aggrecan in 15 instances of these tumors by using immunohistochemistry.
- The study found that both markers were present in normal salivary glands and indicated a transition process in the tumor that suggests how the neoplastic cells might change type, contributing to the tumor's varied tissue structure.
Article Abstract
Pleomorphic adenoma is the most common salivary gland tumor with annual incidence of 2-3.5/100 000 in population. The histogenesis of salivary gland pleomorphic adenoma is still unclear. One concept sustains the existence of an epithelial-mesenchymal transitions (EMT) process in pleomorphic adenomas by which neoplastic epithelial cells transdifferentiate into mesenchymal cells and leading to tissue heterogeneity from this salivary gland neoplasia. Here we investigate by immunohistochemistry the expression of growth differentiation factor 5 (GDF5) and aggrecan in 15 cases of salivary gland pleomorphic adenomas. We found that both markers were present in normal salivary gland, mainly in the cells that line striated and intercalated ducts suggesting their involvement in the morphogenesis of this duct system. A constant positive reactivity for both markers was recorded in transition regions from tubular proliferative units to myxoid areas suggesting the involvement of an EMT process during the tumorigenesis of such salivary gland neoplasia. Also, both markers may be implicated in the transdifferentiation of neoplastic myoepithelial cells from the myxoid zones to lacuna cells of adjacent chondroid areas completing the morphology of this salivary gland tumor.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
NISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08).
BMJ Oncol
October 2023
Biostatistics Department, Centre Leon Berard, Lyon, France.
Objective: Salivary gland cancers (SGC) are rare cancers with currently no standard treatment for recurrent/metastatic disease. Based on checkpoint inhibitors benefit in a broad range of tumours, NIvolumab in Salivary gland CArcinoma of the Head and Neck (NISCAHN) evaluated nivolumab efficacy in SGC.
Methods And Analysis: In this phase II single-stage Fleming design, patients with SGC with a progressive disease progression within 6 months prior to entering the study, were divided into ACC (adenoid cytic carcinoma) and non-ACC.
Nivolumab in salivary gland cancers: confronting the challenges of unlocking the therapeutic benefits of immunotherapy for rare diseases.
BMJ Oncol
October 2023
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Cytological features of oncocytic pleomorphic adenoma of the salivary gland: Using the Milan classification system to report 3 patients.
Mol Clin Oncol
March 2025
Department of Pathology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-8686, Japan.
Pleomorphic adenoma (PA) is the most common salivary gland tumour. Pre-operative fine-needle aspiration (FNA) is currently one of the most widely used cytological examination techniques for the diagnosis of salivary gland tumours. Because PA exhibits characteristic cytological features, cytological diagnosis is straightforward in most cases.
View Article and Find Full Text PDFSurgical management of benign tumors of the parotid gland: the advantages of extracapsular dissection compared to traditional surgical techniques.
Front Surg
January 2025
General Surgery III, Department of General Surgery and Medical-Surgical Specialties, University of Catania, AOU Policlinico "G. Rodolico - San Marco", Catania, Italy.
Introduction: Salivary gland tumors represent only 3%-6% of all head and neck neoplasms, and approximately 70% of these tumors are located in the parotid gland. Most of these tumors are found in the more abundant superficial portion of the parotid gland, lateral to the facial nerve (FN). For many years, the location of the facial nerve between the superficial and deep segments of the parotid gland hindered adequate tumor extirpation.
View Article and Find Full Text PDFSurgical non-aggressive approach for the delivery of 4 cm salivary stone from the submandibular gland duct: Avoiding salivary gland removal - A case report.
Int J Surg Case Rep
January 2025
Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Tishreen University Hospital, Tishreen University, Latakia, Syria. Electronic address:
Introduction And Importance: Salivary calculi represent the most common salivary gland disease. It can vary significantly in size, ranging from less than 1 mm to several centimeters. As the size of the stone increases, the surgical approach becomes more complex and the function of the gland may be compromised, potentially necessitating total gland removal.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!